Adverum Biotechnologies, Inc. (ADVM) Covered Calls

There are no covered calls available for Adverum Biotechnologies, Inc..

Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.

Want to make money with covered calls? Sign Up For A Free Trial

Extended Business Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Top 10 Open Interest For Jan 16 Expiration				Top 5 High Yield
1.	NVDA covered calls	6.	AAPL covered calls	1.	OMER covered calls
2.	INTC covered calls	7.	NIO covered calls	2.	RARE covered calls
3.	TLT covered calls	8.	GLD covered calls	3.	SOC covered calls
4.	IBIT covered calls	9.	NFLX covered calls	4.	DAWN covered calls
5.	SLV covered calls	10.	ASST covered calls	5.	EOSE covered calls

Want more examples? ADV Covered Calls | AEE Covered Calls